Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer

Swedish biotech firm Aqilion has acquired a phase-1 ready candidate from Leo Pharma, and the firm is aiming to address a high unmet medical need in the form of the inflammation disease, eosinophilic esophagitis. Through the deal, Leo Pharma also becomes a shareholder of Aqilion.
Leo Pharma sells phase-I ready drug candidate and becomes a shareholder in Swedish buyer Aqilion | Photo: Leo Pharma / PR
Leo Pharma sells phase-I ready drug candidate and becomes a shareholder in Swedish buyer Aqilion | Photo: Leo Pharma / PR
by albert rønning-andersson, translated by daniel pedersen

International attention continues to be fixed on Leo Pharma, which saw its CEO Catherine Mazzacco step down with immediate effect last week.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading